Related Experiment Video
Updated: Apr 17, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Treatment of diffuse alveolar hemorrhage secondary to lupus erythematosus with recombinant activated factor VII
Raúl Carrillo Esper1, Isis Espinoza de Los Monteros Estrada1, Teresa de la Torre León1
1Unidad de Terapia Intensiva, Fundación Clínica Médica Sur, Puente de Piedra 150, Col. Toriello Guerra. Delegación Tlalpan, Mexico, DF 14050 Mexico.
Abstract:
Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication in patients with autoimmune diseases who are undergoing chemotherapy or have had hematopoietic stem cell transplantation. The use of recombinant factor VIIa (rFVIIa) to treat the acute phase of DAH by endobronchial bronchoscopy has been shown to have a significant clinical impact on the survival and evolution of these patients. We report a clinical case of a patient with DAH secondary to systemic lupus erythematosus (SLE) who was treated with rFVIIa administered using a jet nebulizer, obtaining an adequate hemostatic effect with immediate control of DAH and a significant improvement in gas exchange.
Related Concept Videos
Pulmonary Embolism III: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Venous Thrombosis III: Interprofessional Care
Acute Respiratory Failure-IV

